Back

Type of P2Y12 inhibitor at the acute stage and one-year mortality in acute myocardial infarction. The FAST-MI programme

28 August 2018 (16:45 - 16:55)
Organised by:
Congress Presentation Part of: Oral P2Y12 inhibitors in acute coronary syndromes: are they all equal? Pharmacotherapy ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Nicolas Danchin

Saint Joseph Hospital, Paris (France)

5 More presentations in this session

Presentation thumbnail
A head-to-head comparison of uniform prasugrel treatment vs. clopidogrel treatment for confirmed responders in acute coronary syndrome patients: results from the randomized TROPICAL-ACS trial
Doctor R. Hein (Munich, DE)
Abstract Slides Video
Presentation thumbnail
Prasugrel vs Ticagrelor in patients with acute coronary syndrome and diabetes: a propensity match substudy of RENAMI
Doctor M. Bertaina (Turin, IT)
Abstract Slides Video
Presentation thumbnail
Next generation P2Y12 inhibitors improve survival in ACS: An analysis from the British Cardiovascular Intervention Society database.
Doctor H. Contractor (Manchester, GB)
Abstract Slides Video
Presentation thumbnail
Prognostic impact of the new P2Y12 (ticagrelor and prasugrel) versus clopidogrel in acute coronary syndrome patients in relation to renal function
Mrs M. Castineira Busto (Vigo, ES)
Abstract Slides Video
Presentation thumbnail
The OPTIDUAL trial: long term follow-up
Professor G. Helft (Paris, FR)
Abstract Video

Access the full session

Session thumbnail
Oral P2Y12 inhibitors in acute coronary syndromes: are they all equal?

The Event

Event poster

ESC Congress 2018

28 August 2018 16:45 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources